The recent discontinuation of specific batches of the diabetes drug Ozempic by Novo Nordisk has raised concerns among patients and healthcare providers. However, discontinuing lower doses of Ozempic (0.25 mg/0.5 mg) in the 2 mg/1.5 mL strengths is not due to contaminated batches but supply constraints of both Ozempic and Wegovy diabetes/obesity drugs. Novo Nordisk…
Continue reading ›Award-Winning Chicago Personal Injury Lawyer - Securing Justice
for Illinois Injury Victims - Over $450 Million Recovered